Dyadic Applied BioSolutions And Inzymes Announced Planned 2026 Commercialization Of Recombinant Non-animal Bovine Chymosin, Key Enzyme Used In Cheese Production And Dairy Processing

Completion of these development activities represents a contractual milestone under the parties' 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic's proprietary microbial expression platforms. With achievement of this milestone, Dyadic has earned and received a $200,000 milestone payment and remains eligible to receive royalties on future commercial sales.

Chymosin is the primary milk-clotting enzyme used in cheese manufacturing. The global market for dairy processing enzymes is estimated to be approximately $1.5–$2.0 billion annually, driven by increasing global cheese consumption and rising demand for sustainable, fermentation-derived alternatives to traditional animal-sourced enzymes.

"This milestone reflects the strength of our partnership with Dyadic and our shared commitment to delivering innovative, sustainable enzyme solutions to the dairy industry," said Michael Fooken Jensen, CEO of Inzymes ApS. "With final development activities successfully completed, we are advancing with preparations for commercialization in 2026. By combining Dyadic's high-productivity microbial platforms with our scale-up and commercialization expertise, we are positioning this non-animal chymosin to meet evolving customer requirements for performance, consistency, and supply reliability."

Joe Hazelton, President and COO of Dyadic Applied BioSolutions, stated: "The achievement of this development milestone marks important progress under our agreement with Inzymes and demonstrates our ability to advance programs from development through commercialization. We believe our microbial expression platforms support efficient development and scalable manufacturing, and we look forward to expanding into additional enzyme and protein opportunities across our business segments."

Additional non-animal dairy enzyme candidates continue to progress under the collaboration, supporting expansion of the companies' portfolio within the growing market for fermentation-derived food enzymes. The successful completion of final development steps toward commercialization further reinforces the versatility of Dyadic's platforms across food and nutrition, life sciences, and industrial biotechnology applications.